Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988
ABSTRACT The orally inhaled route of administration for respiratory indications can maximize drug exposure to the site of action (lung) to increase efficacy while minimizing systemic exposure to achieve an improved safety profile. However, due to the difficulty of taking samples from different regio...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.70027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221080384372736 |
|---|---|
| author | Rui Zhu Ian Sorrell Fang Ma Miaoran Ning Yoen‐Ju Son Gaohong She Tom De Bruyn Joshua Galanter Nastya Kassir Ryan Owen Masoud Jamei Iain Gardner Yuan Chen |
| author_facet | Rui Zhu Ian Sorrell Fang Ma Miaoran Ning Yoen‐Ju Son Gaohong She Tom De Bruyn Joshua Galanter Nastya Kassir Ryan Owen Masoud Jamei Iain Gardner Yuan Chen |
| author_sort | Rui Zhu |
| collection | DOAJ |
| description | ABSTRACT The orally inhaled route of administration for respiratory indications can maximize drug exposure to the site of action (lung) to increase efficacy while minimizing systemic exposure to achieve an improved safety profile. However, due to the difficulty of taking samples from different regions of the human lung, often only systemic pharmacokinetic (PK) samples are taken and assumed to be reflective of the lung PK of the compound, which may not always be the case. In this study, a mechanistic lung physiologically based pharmacokinetic (PBPK) model was built using a middle‐out approach (i.e., combining elements of bottom‐up prediction and using clinical data to inform some model parameters) to predict plasma and lung PK of an orally inhaled TMEM16A potentiator GDC‐6988 in humans. The lung PBPK model accounted for lung deposition, lung and oral absorption, systemic clearance, and tissue distribution. The model was refined using data from a Phase 1b study with dry powder (DP) formulation and was also verified using data from a Phase 1 study with a nebulized (Neb) formulation. The refined model adequately captures the observed GDC‐6988 plasma PK profiles in both the DP and Neb studies and allows prediction of the regional lung fluid and tissue concentrations. The sensitivity analyses showed that the systemic Cmax depended on the ratio of airway to alveolar deposition, but this did not impact the AUC. This novel mechanistic lung PBPK modeling framework could be applied to predict plasma and regional lung exposure and inform the early clinical development of inhaled molecules (e.g., dose selection). |
| format | Article |
| id | doaj-art-5392b65fbca140a2b983288cb9056d85 |
| institution | OA Journals |
| issn | 2163-8306 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | CPT: Pharmacometrics & Systems Pharmacology |
| spelling | doaj-art-5392b65fbca140a2b983288cb9056d852025-08-20T02:06:49ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062025-06-011461087109710.1002/psp4.70027Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988Rui Zhu0Ian Sorrell1Fang Ma2Miaoran Ning3Yoen‐Ju Son4Gaohong She5Tom De Bruyn6Joshua Galanter7Nastya Kassir8Ryan Owen9Masoud Jamei10Iain Gardner11Yuan Chen12Genentech, Inc. South San Francisco California USACertara UK Limited Sheffield UKGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USACertara UK Limited Sheffield UKCertara UK Limited Sheffield UKGenentech, Inc. South San Francisco California USAABSTRACT The orally inhaled route of administration for respiratory indications can maximize drug exposure to the site of action (lung) to increase efficacy while minimizing systemic exposure to achieve an improved safety profile. However, due to the difficulty of taking samples from different regions of the human lung, often only systemic pharmacokinetic (PK) samples are taken and assumed to be reflective of the lung PK of the compound, which may not always be the case. In this study, a mechanistic lung physiologically based pharmacokinetic (PBPK) model was built using a middle‐out approach (i.e., combining elements of bottom‐up prediction and using clinical data to inform some model parameters) to predict plasma and lung PK of an orally inhaled TMEM16A potentiator GDC‐6988 in humans. The lung PBPK model accounted for lung deposition, lung and oral absorption, systemic clearance, and tissue distribution. The model was refined using data from a Phase 1b study with dry powder (DP) formulation and was also verified using data from a Phase 1 study with a nebulized (Neb) formulation. The refined model adequately captures the observed GDC‐6988 plasma PK profiles in both the DP and Neb studies and allows prediction of the regional lung fluid and tissue concentrations. The sensitivity analyses showed that the systemic Cmax depended on the ratio of airway to alveolar deposition, but this did not impact the AUC. This novel mechanistic lung PBPK modeling framework could be applied to predict plasma and regional lung exposure and inform the early clinical development of inhaled molecules (e.g., dose selection).https://doi.org/10.1002/psp4.70027 |
| spellingShingle | Rui Zhu Ian Sorrell Fang Ma Miaoran Ning Yoen‐Ju Son Gaohong She Tom De Bruyn Joshua Galanter Nastya Kassir Ryan Owen Masoud Jamei Iain Gardner Yuan Chen Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988 CPT: Pharmacometrics & Systems Pharmacology |
| title | Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988 |
| title_full | Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988 |
| title_fullStr | Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988 |
| title_full_unstemmed | Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988 |
| title_short | Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988 |
| title_sort | mechanistic physiologically based pharmacokinetic modeling of dry powder and nebulized formulations of orally inhaled tmem16a potentiator gdc 6988 |
| url | https://doi.org/10.1002/psp4.70027 |
| work_keys_str_mv | AT ruizhu mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT iansorrell mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT fangma mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT miaoranning mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT yoenjuson mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT gaohongshe mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT tomdebruyn mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT joshuagalanter mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT nastyakassir mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT ryanowen mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT masoudjamei mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT iaingardner mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 AT yuanchen mechanisticphysiologicallybasedpharmacokineticmodelingofdrypowderandnebulizedformulationsoforallyinhaledtmem16apotentiatorgdc6988 |